Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebivolol in hypertension and diastolic dysfunction
NCT01961323Phase 4Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2012
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nebivolol in hypertension (HTN) and left ventricular diastolic dysfunction (LVDD), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Improvement in Exercise Tolerance at 6 months. Started Mar 2012; status: completed.
02
Drugs
nebivolol
03
Conditions
hypertension (HTN)left ventricular diastolic dysfunction (LVDD)
Beyond the preview
Go deeper on NCT01961323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961323.